BioWorld

April 16, 2009

Sanofi Seeks to Beef Up Cancer Line with BiPar

Paris-based Sanofi-Aventis Group is buying cancer drugmaker BiPar Sciences Inc. in a deal potentially worth $500 million for the Brisbane, Calif.-based firm and its investors. (BioWorld Today) Read More

Lycera Raises $36M Series A for Novel Autoimmune Targets

Infinity Halts Tumor Trial Due to High Mortality Data

Synageva Raises $30M to Advance Antibodies Program

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...